JP5746196B2 - Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 - Google Patents

Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 Download PDF

Info

Publication number
JP5746196B2
JP5746196B2 JP2012534798A JP2012534798A JP5746196B2 JP 5746196 B2 JP5746196 B2 JP 5746196B2 JP 2012534798 A JP2012534798 A JP 2012534798A JP 2012534798 A JP2012534798 A JP 2012534798A JP 5746196 B2 JP5746196 B2 JP 5746196B2
Authority
JP
Japan
Prior art keywords
hiv infection
therapeutic agent
inhibitor
hiv
infection according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012534798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508349A (ja
JP2013508349A5 (https=
Inventor
ディナレロ チャールズ
ディナレロ チャールズ
フォサッティ ジャンルカ
フォサッティ ジャンルカ
マスカーニ パオロ
マスカーニ パオロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of JP2013508349A publication Critical patent/JP2013508349A/ja
Publication of JP2013508349A5 publication Critical patent/JP2013508349A5/ja
Application granted granted Critical
Publication of JP5746196B2 publication Critical patent/JP5746196B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012534798A 2009-10-23 2010-09-14 Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 Expired - Fee Related JP5746196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (it) 2009-10-23 2009-10-23 Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
ITMI2009A001837 2009-10-23
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (3)

Publication Number Publication Date
JP2013508349A JP2013508349A (ja) 2013-03-07
JP2013508349A5 JP2013508349A5 (https=) 2013-05-09
JP5746196B2 true JP5746196B2 (ja) 2015-07-08

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534798A Expired - Fee Related JP5746196B2 (ja) 2009-10-23 2010-09-14 Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体

Country Status (10)

Country Link
US (1) US8637702B2 (https=)
EP (1) EP2490682A1 (https=)
JP (1) JP5746196B2 (https=)
KR (1) KR101687644B1 (https=)
CN (1) CN102548551A (https=)
BR (1) BR112012008780A2 (https=)
CA (1) CA2773210C (https=)
IN (1) IN2012DN03387A (https=)
IT (1) IT1396915B1 (https=)
WO (1) WO2011048514A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6272773B2 (ja) * 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
CN107007580A (zh) 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
JP2007529548A (ja) * 2004-03-18 2007-10-25 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖベンズアミド化合物およびベンゾアート化合物
ITMI20041347A1 (it) * 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
US20100324034A1 (en) 2007-02-08 2010-12-23 Hazuda Daria J Methods of Using SAHA for Treating HIV Infection

Also Published As

Publication number Publication date
CN102548551A (zh) 2012-07-04
ITMI20091837A1 (it) 2011-04-23
KR20120083356A (ko) 2012-07-25
IT1396915B1 (it) 2012-12-20
KR101687644B1 (ko) 2016-12-19
US8637702B2 (en) 2014-01-28
JP2013508349A (ja) 2013-03-07
IN2012DN03387A (https=) 2015-10-23
CA2773210C (en) 2017-01-03
US20120203014A1 (en) 2012-08-09
WO2011048514A1 (en) 2011-04-28
CA2773210A1 (en) 2011-04-28
BR112012008780A2 (pt) 2020-12-01
EP2490682A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US20240390375A1 (en) Methods and compositions for treating viral or virally-induced conditions
JP5746196B2 (ja) Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体
Aboul-Fadl et al. Anti-tubercular activity of isatin derivatives
US8247613B2 (en) Methods and compositions for the synergistic activation of latent HIV
US20060009527A1 (en) Method of treating TRX mediated diseases
KR20130028149A (ko) 암의 치료
US20210060014A1 (en) Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
JP2016536354A (ja) 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ
US10184933B2 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
US9352010B2 (en) Treatment of HIV-1 infection and AIDS
RU2009120115A (ru) Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом
Szaniawski et al. Senotherapeutics and HIV-1 persistence
US10633363B2 (en) EPAC1 activators as HIV latency reversal agents (LRA)
US10975059B2 (en) Small molecule BRD4 modulators for HIV epigenetic regulation
RU2819782C2 (ru) Способы лечения ассоциированных с вирусом форм рака с помощью ингибиторов гистондеацетилазы
US11554123B2 (en) Compositions and methods for reactivating latent HIV-1 infections
Manhiani The role of cytochrome P450 epoxygenase enzymes in renal injury and inflammation with salt sensitive hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150507

R150 Certificate of patent or registration of utility model

Ref document number: 5746196

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees